Clinical Trials (Phase I)

Found 12,614 articles

• Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)

  11/20/2018

  Ipsen and 3BP today announced the first patient has been dosed in a Phase I/II study for the first-in-class radionuclide 177Lu-IPN01087 (formerly known as 3BP-227).

• Astellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual Meeting

  11/19/2018

  Abstracts include updated results from Phase 1 study of gilteritinib in patients with newly diagnosed AML

• CStone initiates a bridging Phase I clinical trial for PD-1 antibody CS1003 with first patient dosed in China

  11/19/2018

  CStone Pharmaceuticals (CStone) today announced that a first patient has been enrolled and dosed in a Phase I clinical trial in China for the recombinant humanized anti-programmed death-1 (PD-1) monoclonal antibody (mAb) CS1003.

• Vyera Pharmaceuticals Receives FDA Clearance To Initiate A Phase 1 Study Of A New Chemical Entity Designed As A Potential Treatment For Toxoplasmosis

  11/16/2018

  Vyera Pharmaceuticals, LLC announced it plans to initiate a Phase 1 single ascending dose (SAD) study of VYR-006, a novel dihydrofolate reductase (DHFR) inhibitor which Vyera discovered and is developing for the treatment of toxoplasmosis.

• Promentis Pharmaceuticals Announces Successful Completion of Phase 1 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism

  11/16/2018

  Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, today announced it has completed Phase 1 single ascending dose and multiple ascending dose studies for its lead compound, SXC-2023.  

• First-in-Human Trial Launched for Super-Enhancer Inhibitor GZ17-6.02

  11/16/2018

  Genzada Pharmaceuticals USA Inc., a subsidiary of Ionics Life Sciences Limited (Genzada), announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for a Phase 1 human clinical trial of the company’s flagship molecule GZ17-6.02 (6.02) for patients with advanced solid organ tumors or lymphoma.

• 

  Cadent Takes in $40 Million to Advance Its Pipeline, Taps a New CMO

  11/15/2018

  Cadent Therapeutics secured $40 million to advance its lead program, CAD-1883.The company also struck a deal with Novartis to develop NMDA modulators.

• NapaJen Pharma Announces First Patient Dosed in Phase 1 First-in-Human Clinical Trial of Novel RNA Interference (RNAi) Therapeutic

  11/15/2018

  NapaJen Pharma Co., Ltd., a biotherapeutics company leveraging its proprietary immune cell-targeted oligonucleotide delivery technology to develop novel immunotherapeutic agents, today announced dosing of the first patient in a Phase 1 first-in-human clinical trial of NJA-730 in healthy volunteers. 

• Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology

  11/15/2018

  Pulmatrix. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present the results of the recently completed phase 1/1b clinical trial of Pulmazole, an inhaled dry-powder iSPERSE™ formulation of itraconazole, at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology in Seattle, Washington on November 17, 2018.

• Syros Announces Dose Escalation Data from Phase 1 Trial of SY-1365 Demonstrating Proof-of-Mechanism at Tolerable Doses in Patients with Advanced Solid Tumors

  11/15/2018

  Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that data from the dose escalation portion of its Phase 1 trial of SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, demonstrated proof-of-mechanism at tolerable doses in patients with advanced solid tumors.

• Mitsubishi Tanabe Pharma Group Companies To Present New Data On Investigational Oral Formulation Of Edaravone For ALS At 29th International Symposium On ALS/MND

  11/15/2018

  Initial Study Results Show a Single Oral Dose is Expected to Have Similar Pharmacokinetic Parameters as IV Infusion

• BAROnova's TransPyloric Shuttle® (TPS®) Positive Pivotal Trial Data Presented at the 2018 Obesity Week Conference

  11/15/2018

   BAROnova, Inc., a clinical stage medical device company focused on the development of non-surgical solutions for the treatment of obesity, announced today the presentation of primary results of its pivotal trial, the ENDObesity II study, as a late-breaking clinical trial, at the scientific sessions of the 2018 Obesity Week conference.

• Alector Initiates Phase 1 Trial of AL002 for the Treatment of Patients with Alzheimer’s Disease

  11/15/2018

  First Clinical Trial of a Program Designed to Address Multiple Brain Pathologies in Alzheimer’s Disease by Reversing Immune Dysfunction

• Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium

  11/14/2018

  ZW25 Active and Well Tolerated Across Multiple HER2-expressing Tumor Types

• SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection

  11/14/2018

  Data Shows Significant Improvement in Clinically Relevant Endpoints

• Five Prime Therapeutics Initiates Patient Dosing in a Phase 1 Clinical Trial of FPT155, a First-in-Class CD80 Fusion Protein

  11/14/2018

  Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced it initiated patient dosing in a Phase 1 clinical trial of FPT155, a first-in-class CD80 fusion protein.

• Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma

  11/14/2018

  Seattle Genetics, Inc. (Nasdaq:SGEN) announced today dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SEA-BCMA for patients with relapsed or refractory multiple myeloma (MM).

• Bay Labs and Northwestern Medicine Enroll First Patient in Study Using AI Software to Improve Heart Disease Detection

  11/13/2018

  Clinical Trial Evaluates if AI Helps Certified Medical Assistants Perform Echocardiograms and Detect Heart Disease in Primary Care Settings

• Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer

  11/13/2018

  Initiation of Phase 1 Trial Planned for Early 2019

• Ascentage Pharma Presenting New Clinical Data of Novel Dual Bcl-2/Bcl-xL Inhibitor APG-1252 at Asia Conference on Lung Cancer 2018 (ACLC)

  11/13/2018

  Ascentage Pharma Group Corporation, Ltd. announced today that the company presented the new clinical data of the dual Bcl-2/Bcl-xL inhibitor APG-1252.